Skip to main content
. 2021 May 27;13:4233–4240. doi: 10.2147/CMAR.S304820

Table 4.

Best Anti-Tumor Response According to the mRECIST

Lenvatinib Group (n=27) Lenvatinib Plus Camrelizumab Group(n=21)
Complete response 0 (0%) 0 (0%)
Partial response 2 (7.41%) 6 (28.57%)
Stable disease 12 (44.44%) 9 (42.86%)
Progressive disease 13 (38.15%) 6 (28.57%)
Objective Response Rate 7.41% 28.57%
Disease Control Rate 51.85% 71.43%

Note: Responses were evaluated according to modified Response Evaluation Criteria in Solid Tumors version by investigators.